Craig Sauter, MD

Articles

Dr. Sauter on the Potential Role of BTK Inhibitors in Frontline CNS Lymphoma

March 14th 2023

Craig Sauter, MD, discusses where BTK inhibitors could fit into the frontline treatment landscape for patients with central nervous system lymphoma and research aiming to address other unmet needs for this patient population.

Dr. Sauter on Questions Surrounding Novel Therapies in Hematologic Malignancies

February 24th 2023

Craig Sauter, MD, discusses prominent questions surrounding new and emerging therapies in the treatment of patients with hematologic malignancies.

Dr. Sauter on Key Considerations for Posttransplant Pembrolizumab in T-cell NHL

January 4th 2023

Craig Sauter, MD, discusses important considerations regarding the use of pembrolizumab after autologous stem cell transplant in T-cell non-Hodgkin lymphoma.

Dr. Sauter on Pembrolizumab After Stem Cell Transplant in T-Cell NHL

December 19th 2022

Craig Sauter, MD, discusses the investigation of pembrolizumab given after stem cell transplant in T-cell non-Hodgkin lymphoma.

Dr. Hill and Dr. Sauter Consider CAR T-Cell Therapy in Second-Line Setting for DLBCL

November 2nd 2022

Craig Sauter, MD, and Brian T. Hill, MD, PhD, consider CAR T-cell therapy in the second-line setting for patients with diffuse large B-cell lymphoma.

Cleveland Clinic Experts Assess Strategies to Accelerate CAR T-Cell Production

November 2nd 2022

Craig Sauter, MD, and Brian T. Hill, MD, PhD, discuss recent data showing that the CAR T-cell production can be shortened.

Dr. Hill and Dr. Sauter Discuss the Future of CAR T-Cell Products Agents in Lymphoma

November 2nd 2022

Craig Sauter, MD, and Brian T. Hill, MD, PhD, discuss potential directions for CAR T-cell therapy in lymphomas.

Cleveland Clinic Experts Discuss the Potential for Allogeneic CAR T-Cell Agents

November 2nd 2022

Brian T. Hill, MD, PhD, and Craig Sauter, MD, discuss the promise of allogeneic CAR T-cell products.

Dr. Hill and Dr. Sauter Address Financial Toxicity in CAR T-Cell Therapy

November 2nd 2022

Craig Sauter, MD, and Brian T. Hill, MD, PhD, address the issue of financial toxicity in CAR T-cell therapy.

Dr. Sauter on Off-The-Shelf Versus Autologous CAR T-Cell Products in Hematologic Malignancies

June 12th 2020

Craig Sauter, MD, discusses the differences between off-the-shelf and autologous chimeric antigen receptor T-cell products in patients with hematologic malignancies.

Dr. Sauter on CAR T Cells in Real-World Patients With Hematologic Malignancies

February 22nd 2020

Craig Sauter, MD, discusses the anecdotal observational data in real-world patients with hematologic malignancies who received chimeric antigen receptor T-cell therapy.